Japan-based drugmaker Eisai Co's U.S. subsidiary announced on Sunday that i...
- Japan-based drugmaker Eisai Co’s U.S. subsidiary announced on Sunday that it had received approval from the U.S. Food and Drug Administration for its insomnia treatment in adult patients.
The treatment belongs to a new class of medications, which target the oxerin system, joining the ranks with Merck & Co’s Belsomra, which was approved in 2014. Following the DEA scheduling of Dayvigo, which usually takes 90 days, Eisai plans to launch the drug by early April of 2020. However, Eisai pointed some caution is to be taken while on the 10 mg dose as it may cause some difficulty in driving the next day after the medication.
Brasil Últimas Notícias, Brasil Manchetes
Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.
AstraZeneca, Daiichi's breast cancer drug gets accelerated approval from FDAThe U.S. Food and Drug Administration said on Friday it had approved Daiichi San...
Consulte Mais informação »
A Year in the Middle of a Trade War - The Journal. - WSJ Podcasts🎧 Listen: The U.S. announced a 'phase one' trade deal with China last week, halting the trade war. The Journal's Jacob Schlesinger looks back on a year of escalating tariffs.
Consulte Mais informação »
Firm suspends Nord Stream 2 pipeline work over US sanctionsA company operating ships laying sections of a new German-Russian pipeline says it is suspending those activities after the approval of U.S. legislation threatening sanctions
Consulte Mais informação »
U.S. FDA declines to approve GSK drugs division's long acting HIV injectionGlaxoSmithKline's HIV drugs division ViiV Healthcare said on Saturday that ...
Consulte Mais informação »
My Weighted Blanket Helps With Way More Than Just SleepIf stress or insomnia keeps you up at night, this weighted blanket will change your life.
Consulte Mais informação »
UK on track for January 31 Brexit as PM Johnson wins vote on dealBritain is on track for Jan. 31 Brexit as Prime Minister Boris Johnson wins approval for his Brexit deal in parliament
Consulte Mais informação »